Approved indications: Veklury is FDA-approved for the treatment of COVID-19 in adults and pediatric patients (≥28 days old, ≥3 kg) who are hospitalized, and in non-hospitalized patients at high risk for progression to severe COVID-19, including hospitalization or death.

Off-label uses: Use has largely been confined to COVID-19; off-label use for other viral infections is limited and generally investigational, with insufficient evidence for routine clinical use.

Efficacy expectations: In eligible patients treated early in the course of illness, Veklury can reduce the risk of hospitalization or progression to more severe disease and may modestly shorten recovery time in hospitalized patients. Clinical improvement is usually assessed over several days, with earlier use (soon after symptom onset or diagnosis) associated with better outcomes.

Comparison to similar drugs: Unlike oral antivirals such as nirmatrelvir/ritonavir, Veklury requires IV administration but can be used in some patients for whom oral options are not suitable. Its benefit is greatest in selected higher-risk patients and when given early, and it is generally considered one component of a broader COVID-19 treatment strategy that may also include other antivirals and/or immunomodulators, depending on disease severity.

Typical dosing and administration: Veklury is given by intravenous infusion in a healthcare setting. For most adults and adolescents weighing at least 40 kg, a common regimen is 200 mg IV on day 1, followed by 100 mg IV once daily; the usual duration is 3 days for certain non-hospitalized high-risk patients and 5 days (extendable up to 10 days) for many hospitalized patients, depending on disease severity and response. Pediatric dosing for patients weighing 3 kg to <40 kg is weight-based according to product labeling and is also administered by IV infusion.

Special dosing instructions: Infusions are given over a defined period (often 30–120 minutes) and should not be administered as a rapid IV push. Dosing schedules may be adjusted or discontinued based on liver tests, kidney function, or clinical status. The drug is not taken by mouth and is not self-administered at home in standard practice.

Missed doses and overdose: If a scheduled infusion is missed, the patient’s healthcare team will decide when and whether to reschedule based on timing and overall treatment goals; patients should not attempt to compensate on their own. In case of suspected overdose, supportive care and monitoring of vital signs, liver, and kidney function are provided in a clinical setting.

Common side effects: More frequent effects include nausea, headache, and infusion-related reactions (such as flushing, sweating, or changes in blood pressure) that usually occur during or shortly after the IV infusion and are often mild to moderate.

Serious or rare adverse effects: Veklury can cause increases in liver enzymes and, rarely, clinically significant liver injury; it has also been associated with hypersensitivity or anaphylactic reactions during infusion, which require immediate medical attention. Changes in kidney function have been reported, so kidney function is monitored, particularly in patients with pre-existing kidney problems.

Warnings and precautions: Liver tests are checked before and during treatment, and treatment may be stopped if significant liver injury is suspected. Use in pregnancy is based on a benefit–risk assessment; available data have not shown major safety concerns, but information is still limited. For breastfeeding, limited human data are available, so clinicians weigh maternal benefits against potential but unknown risks to the infant. Caution is required in patients with reduced kidney function, especially those with severely impaired renal function, because of accumulation of excipients; dosing decisions follow current product labeling and clinical guidelines. Veklury is approved for adults and for children ≥28 days old and ≥3 kg; safety and dosing in younger or smaller infants are not established.

Overall safety compared with other options: When used in appropriate patients with monitoring, Veklury is generally well tolerated, with a safety profile that is acceptable compared with other systemic antivirals used for COVID-19, though it requires IV access and clinical supervision.

Reporting side effects and safety updates: Patients and caregivers should inform their healthcare provider about any side effects. In the United States, side effects can be reported to FDA MedWatch or to the manufacturer, and updated safety information is made available through product labeling and regulatory safety communications.

Drug and product interactions: Veklury is metabolized and transported by several cellular pathways, and strong inducers or inhibitors of certain enzymes or transporters may theoretically affect its levels, though few major, well-documented interactions are established in routine practice. It is generally compatible with many commonly used COVID-19 therapies when administered according to guidelines, but co-administration with other nephrotoxic or hepatotoxic drugs may increase the risk of kidney or liver problems. Patients should inform their healthcare team about all prescription and over-the-counter medicines, herbal products, and supplements they are using. No specific food interactions are expected, as the drug is given IV, and alcohol interactions are mainly a concern because of additive liver stress.

Precautions and conditions affecting use: Caution is advised in patients with significantly impaired kidney function or liver disease; baseline and periodic tests are recommended. Use in pregnancy or breastfeeding requires individualized assessment of potential benefits and risks. Clinicians also consider other coexisting conditions (such as cardiovascular disease or immunosuppression) and concurrent therapies when deciding on treatment.

Monitoring needs: Before and during treatment, liver function tests (such as ALT and AST) and kidney function (such as serum creatinine and estimated glomerular filtration rate) are typically monitored. Clinical status, including breathing and oxygen needs, is closely followed in hospitalized patients, and infusion sites are observed for reactions during and after administration.

Q: What is Veklury used for?
A: Veklury is an antiviral medicine given by IV infusion to treat COVID-19 in adults and certain children, including some who are hospitalized and some high-risk patients who are not hospitalized.

Q: How is Veklury given and how long does treatment last?
A: Veklury is administered through a vein in a clinic or hospital, usually once a day for 3 to 5 days, and in some hospitalized patients treatment may be extended up to 10 days based on how they are doing.

Q: When will I start to feel better after receiving Veklury?
A: Some patients, especially those treated early in the illness, may begin to improve over several days, but the main goal is to lower the risk of getting sicker or needing hospitalization rather than to provide immediate symptom relief.

Q: Can I get Veklury at home or take it as a pill?
A: No, Veklury is currently available only as an intravenous infusion prepared and given by healthcare professionals, not as an oral pill or home treatment.

Q: Is Veklury safe if I am pregnant or breastfeeding?
A: Limited data are available, so decisions about using Veklury during pregnancy or breastfeeding are made individually, weighing your risk from COVID-19 against the potential but not fully known risks of the medicine; discuss this carefully with your healthcare provider.

Storage: Veklury vials are stored and prepared by healthcare professionals in a clinical setting; patients typically do not store this medicine at home.

Disposal: Unused drug and used supplies are disposed of by the clinic or hospital as medical waste; patients usually do not need to handle disposal themselves.